AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
As antibody–drug conjugates (ADCs) and immune checkpoint inhibitors continue to grab a lot of attention as transformative cancer therapies, they would appear to leave little room ...
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...